U.S. markets close in 1 hour 58 minutes

Artivion, Inc. (AORT)

NYSE - Nasdaq Precio en tiempo real. Moneda en USD.
Añadir a la lista de seguimiento
26.27+0.35 (+1.35%)
A partir del 01:57PM EDT. Mercado abierto.

Artivion, Inc.

1655 Roberts Boulevard N.W.
Kennesaw, GA 30144
United States
770 419 3355
https://artivion.com

Sector(es)Healthcare
IndustriaMedical Devices
Empleados a tiempo completo1,500

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. James Patrick MackinChairman, President & CEO2.37M194.62k1967
Mr. Lance A. Berry CPAExecutive VP of Finance, COO & CFO138.36kN/D1972
Ms. Amy D. Horton CPAVP & Chief Accounting Officer621.26k118.2k1970
Ms. Jean F. Holloway Esq.Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary841.43kN/D1957
Mr. John E. DavisSenior VP & Chief Commercial Officer802.02k27.55k1965
Mr. Matthew A. GetzVP of Human Resources & Chief Human Resources OfficerN/DN/D1969
Dr. Marshall S. Stanton M.D.Senior VP of Clinical Research & Chief Medical Officer615.55kN/D1957
Dr. Robert C. ThomsonVice President of Research & DevelopmentN/DN/D1970
Mr. Florian TyrsVice President of Global OperationsN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Gestión corporativa

La calificación ISS Governance QuickScore de Artivion, Inc. a partir del 1 de octubre de 2024 es 4. Las puntuaciones principales son Auditoría: 3; Junta: 5; Derechos del accionista: 4; Compensación: 4.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.